<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521062</url>
  </required_header>
  <id_info>
    <org_study_id>5768</org_study_id>
    <nct_id>NCT04521062</nct_id>
  </id_info>
  <brief_title>Dilapan-S® for Induction of Labor The Feasibility Study</brief_title>
  <acronym>DILATE</acronym>
  <official_title>Dilapan-S® for Induction of Labor - Assessing ouTpatient Placement and Effectiveness - The Feasibility Study (The DILATE Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective feasibility study to investigate Dilapan-S® as an outpatient method of&#xD;
      cervical ripening in low risk pregnancies &gt;=39 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2019, the ARRIVE trial was published, demonstrating that in low risk nulliparous women,&#xD;
      induction of labor at 39 weeks was associated with a decreased risk for hypertensive&#xD;
      disorders of pregnancy and decreased risk for cesarean without any increased risk for severe&#xD;
      neonatal complications or perinatal death. (1) Based on the results of this trial, hospitals&#xD;
      have been questioning the feasibility of implementing a protocol which offers induction of&#xD;
      labor to low risk women at ≥39 weeks. There are concerns regarding the ability of a busy&#xD;
      labor and delivery to accommodate women presenting for inductions with an unfavorable cervix.&#xD;
      Outpatient mechanical cervical ripening would allow for women to start the process of&#xD;
      induction of labor at home. This is appealing because cervical ripening is typically the&#xD;
      longest component of the induction process. Mechanical cervical ripening is the process by&#xD;
      which balloons or dilators are placed into the cervix.&#xD;
&#xD;
      There is lack of evidence on Dilapan-S® as an outpatient method of cervical ripening despite&#xD;
      the potential benefits of increased maternal satisfaction and decreased length of hospital&#xD;
      stay. With this in mind we propose a preliminary study of 40 women to assess for feasibility&#xD;
      of performing a large randomized control trial and assess safety with outpatient treatment.&#xD;
      This initial study is intended to assess the feasibility of outpatient cervical ripening,&#xD;
      next day induction of labor, and safety. After completion of this feasibility study, the&#xD;
      investigators plan to initiate a randomized control trial to assess the efficacy of&#xD;
      outpatient Dilapan-S® for mechanical cervical ripening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to delivery</measure>
    <time_frame>from induction start to delivery, estimated average 12 hours</time_frame>
    <description>Length of time between induction of labor start and delivery (hours)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>APGAR score at 1and 5 min</measure>
    <time_frame>1 and 5 minutes after birth</time_frame>
    <description>APGAR score (number 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with maternal infection</measure>
    <time_frame>during hospital admission, average 4 days</time_frame>
    <description>chorioamnionitis, endometritis - Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NICU admission</measure>
    <time_frame>through maternal hospital admission, average 4 days</time_frame>
    <description>Neonatal admission to NICU (any admission) - Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for neonatal antibiotics</measure>
    <time_frame>in the first 72 hours after delivery</time_frame>
    <description>any antibiotic use in postnatal period (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for resipiratory support</measure>
    <time_frame>during hospital admission, average 4 days</time_frame>
    <description>any respiratory interventions after birth for neonate (composite of oxygen administration, respiratory distress syndrome, CPAP, intubation) (yes/No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mode of delivery</measure>
    <time_frame>one time at the time of delivery, variable to occur during hospital admission, average 4 days</time_frame>
    <description>cesarean or vaginal (coded as cesarean delivery Y/N or vaginal delivery Y/N)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Dilapan S</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placement of dilators</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dilapan S</intervention_name>
    <description>Placement of Dilapan S</description>
    <arm_group_label>Dilapan S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Planned induction of labor ≥ 39 weeks&#xD;
&#xD;
          2. Singleton gestation&#xD;
&#xD;
          3. Vertex presentation&#xD;
&#xD;
          4. Cervical dilation &lt;3cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Placenta previa&#xD;
&#xD;
          2. Placenta accreta&#xD;
&#xD;
          3. Vasa previa&#xD;
&#xD;
          4. Preterm prelabor rupture of membranes&#xD;
&#xD;
          5. Non-english speaking&#xD;
&#xD;
          6. &lt;18 years old&#xD;
&#xD;
          7. Multiple gestation&#xD;
&#xD;
          8. Prior cesarean delivery&#xD;
&#xD;
          9. Prior myomectomy&#xD;
&#xD;
         10. Fetal malpresentation&#xD;
&#xD;
         11. Active vaginal bleeding&#xD;
&#xD;
         12. Cervical dilation &gt;1 cm&#xD;
&#xD;
         13. Uterine anomaly (didelphysis, bicornuate)&#xD;
&#xD;
         14. Intrauterine growth restriction &lt;10th%&#xD;
&#xD;
         15. Fetal anomalies&#xD;
&#xD;
         16. Requirements to be inpatient&#xD;
&#xD;
         17. Polyhydramnios (AFI&gt;25cm or MVP&gt;8cm)&#xD;
&#xD;
         18. Chronic hypertension on medications&#xD;
&#xD;
         19. Gestational hypertension/preeclampsia&#xD;
&#xD;
         20. GDMA2, DM1, DM2&#xD;
&#xD;
         21. Hepatitis B or C&#xD;
&#xD;
         22. HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Lynch, MD</last_name>
    <phone>518-264-3217</phone>
    <email>lyncht2@amc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Lynch</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical ripening</keyword>
  <keyword>induction of labor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

